Literature DB >> 9802860

Nonadhesive liquid embolic agent for cerebral arteriovenous malformations: preliminary histopathological studies in swine rete mirabile.

Y Murayama1, F Viñuela, A Ulhoa, Y Akiba, G R Duckwiler, Y P Gobin, H V Vinters, R J Greff.   

Abstract

OBJECTIVE: To assess acute and chronic histopathological changes observed in a swine arteriovenous malformation model after endovascular delivery of Embolyx E (Micro Therapeutics Inc., San Clemente, CA) and its organic solvent dimethyl sulfoxide (DMSO). To develop standard endovascular delivery techniques of Embolyx through microcatheters into swine rete mirabile (RMB).
METHODS: Forty RMBs in 22 swine were used to analyze acute and chronic angiographic and histological changes after superselective delivery of Embolyx E and/or its organic solvent (DMSO). Four RMBs (two for DMSO and two for Embolyx E study) were used as control specimens. Angiographic and histological evaluations were obtained 18 days, 1 month, 3 months, and 6 months after the procedure. Particular attention was paid to the presence of focal or diffuse angionecrosis, arterial revascularization, and perivascular inflammatory response.
RESULTS: Staged and/or continuous delivery of Embolyx E were performed through the DMSO-compatible microcatheters without untoward catheter "gluing." All subacute/chronic specimens embolized with Embolyx E showed no evidence of angiographic recanalization. Twelve RMBs were used in acute studies, and all specimens showed no evidence of angionecrosis or aggressive inflammatory reaction. Subacute and chronic (total, n = 14) histological examinations of the RMBs showed mild inflammatory response manifested by monocellular infiltration and scattered foreign body giant cell reaction. In the 9 of 14 subacute and chronic specimens, focal disruption of elastica was observed along with embolic materials. Fourteen RMBs in eight swine were used to determine the safety range for DMSO injection. Two RMBs were used as control specimens. Rapid intra-arterial delivery (0.5 ml/5-15 s, n = 6) of DMSO caused angiographic vasospasm and histological endothelial necrosis. Slow injection (0.5 ml/30-120 s, n = 8) of DMSO showed minimum or no angiographic vasospasm, minimal adventitial inflammatory response, and no clinical complications.
CONCLUSION: Embolyx E, an occlusive and nonadhesive embolic agent, is capable of producing permanent occlusion of swine RMB with the development of mild intra- and perivascular inflammatory changes and no clinical complications. The slow endovascular delivery of DMSO produces no untoward angiographic, pathological, or clinical changes. A fast injection of DMSO causes endothelial necrosis and severe inflammatory response in the arterial wall. This embolic material seems to have appropriate biochemical, anatomic, and histopathological characteristics to be used in the treatment of cerebral arteriovenous malformations or vascular cranial base tumors.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9802860     DOI: 10.1097/00006123-199811000-00081

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  62 in total

1.  Cervical epidural arteriovenous fistula presenting with radiculopathy: transvenous embolization using Onyx.

Authors:  G Dabus; A Nimmagadda; E J Russell
Journal:  Interv Neuroradiol       Date:  2011-10-17       Impact factor: 1.610

2.  Basics and Principles in the Application of Onyx LD Liquid Embolic System in the Endovascular Treatment of Cerebral Arteriovenous Malformations.

Authors:  R Siekmann
Journal:  Interv Neuroradiol       Date:  2005-10-27       Impact factor: 1.610

3.  Transvenous Treatment of a Dural Arteriovenous Fistula of the Transverse Sinus by Embolization with Platinum Coils and Onyx HD 500+.

Authors:  R Siekmann; W Weber; B Kis; D Kühne
Journal:  Interv Neuroradiol       Date:  2005-10-26       Impact factor: 1.610

4.  Preliminary experience with precipitating hydrophobic injectable liquid in brain arteriovenous malformations.

Authors:  Naci Koçer; Hakan Hanımoğlu; Şebnem Batur; Sedat Giray Kandemirli; Osman Kızılkılıç; Zihni Sanus; Büge Öz; Civan Işlak; Mehmet Yaşar Kaynar
Journal:  Diagn Interv Radiol       Date:  2016 Mar-Apr       Impact factor: 2.630

5.  The use of Onyx for embolization of peripheral vascular malformations in pediatric patients.

Authors:  Murat Cantasdemir; Fatih Gulsen; Serdar Solak; Gokce Yalcin Gulsen; Fatih Kantarci; Furuzan Numan
Journal:  Pediatr Surg Int       Date:  2012-01-22       Impact factor: 1.827

6.  Transvenous treatment of spontaneous dural carotid-cavernous fistulas using a combination of detachable coils and Onyx.

Authors:  S Suzuki; D W Lee; R Jahan; G R Duckwiler; F Viñuela
Journal:  AJNR Am J Neuroradiol       Date:  2006 Jun-Jul       Impact factor: 3.825

7.  New thermoreversible liquid embolic agent for embolotherapy: technical report.

Authors:  Hiroyuki Takao; Yuichi Murayama; Masaki Ebara; Toshihiro Ishibashi; Takayuki Saguchi; Koreaki Irie; Hiroshi Yoshioka; Yuichi Mori; Fernando Vinuela; Toshiaki Abe
Journal:  Neuroradiology       Date:  2008-10-21       Impact factor: 2.804

8.  [Potential and limitations of modern embolization therapy].

Authors:  W A Wohlgemuth; P Ostertag; W Uller
Journal:  HNO       Date:  2014-01       Impact factor: 1.284

9.  Experimental study of temperature-sensitive chitosan/β-glycerophosphate embolic material in embolizing the basicranial rete mirabile in swines.

Authors:  Xianbin Ning; Changfu Zhao; Jinfeng Pang; Zhaoyi Ding; Yubo Wang; Kan Xu; Hao Chen; Bingwei Li; Q I Luo
Journal:  Exp Ther Med       Date:  2015-05-07       Impact factor: 2.447

10.  Liquid 2-poly-hydroxyethyl-methacrylate embolization of experimental arteriovenous malformations: feasibility study.

Authors:  Joachim Klisch; Lin Yin; Flavio Requejo; Barbara Eissner; Kai M Scheufler; Ralf Kubalek; Markus Buechner; Axel Pagenstecher; Heiner Nagursky; Martin Schumacher
Journal:  AJNR Am J Neuroradiol       Date:  2002-03       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.